# Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure

Study · id `cardio:ct-nct02357615` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02357615](<https://clinicaltrials.gov/study/NCT02357615>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02357615

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 244 participants.

## Technical summary

Registry record NCT02357615. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 244 participants (planned count; ClinicalTrials.gov record NCT02357615, source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)
- Start date: 2014-12 (registry gives no type) (ClinicalTrials.gov record NCT02357615, source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)
- Primary completion: 2015-06 (anticipated) (ClinicalTrials.gov record NCT02357615, source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)
- Completion: 2015-09 (anticipated) (ClinicalTrials.gov record NCT02357615, source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02357615, source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02357615-2015-02-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
- Condition: Essential Hypertension
- Intervention (Drug): nifedipine CR tablets (Xin Ran)
- Intervention (Drug): Adalat
- Lead sponsor: Shanghai Shyndec Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 05fc2aa4786a30b942f4304be18bd38d9bf3ec9fb4c7260ebc30441a900acec1
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
